ClinicalTrials.gg
CompletedNCT01364454Updated Aug 19, 2016

General Practitioners (GP) Involvement in Colorectal Cancer (CRC) Screening

An Early Phase 1 interventional study of Eligible patients' paper-based reminder in Colorectal Cancer, sponsored by Paris 12 Val de Marne University. Completed at 1 site in France. Open to participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-08-19.

Sponsored by Paris 12 Val de Marne University · Early Phase 1, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
8,140
Allocation
Randomized
Ages
50 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 583 studies in Colorectal Neoplasms with a site in France — 111 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.

Enrollment
9th of 464
8,140 · median 152
Started
2010
with 21 others
Phase 1
61 of 583
15 open now
Registered
131st of 583
by date

Among the 583 studies in Colorectal Neoplasms with a site in France, this one is the 9th largest by enrollment of the 464 interventional ones that give a count, is one of 22 that started in 2010, is one of 61 in phase 1, and was the 131st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

111 of the 583 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 50 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 583 studies in Colorectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

Screening for ColoRectal Cancer (CRC) is widely recommended because of compelling evidence that it reduces mortality from CRC and that it's cost-effective. In France, there is a national CRC screening programme inviting people aged 50-74 years by mail to consult their General Practitioner (GP) for a free on charge Faecal Occult Blood test deliverance every two years. Participation is a key factor for the screening programs success. High levels of screening uptake and the continued participation to regular screening must be achieved and maintained in the targeted population if the enormous potential of CRC screening is to be realised. Screening rates of various international programs vary widely (20-52%) and the participation is insufficient in the most settings. Therefore, a better understanding of facilitating and hindering factors of patient participation can guide interventions to improve CRC screening rates. They include patients and physicians' factors. One issue is about GPs practice. GP involvement has been shown to improve the participation in the CRC screening. This study aims to assess the effectiveness of an intervention targeting GPs to increase patient participation in the CRC screening. Volunteer GPs will be randomly assigned to either the intervention group or to usual care (control group) and they will be followed one year. The intervention consists in providing every four months to the experimental group a list of their patients who are eligible but did not proceed yet to the screening. In both groups, patient participation in the screening will be measured at the end of the study.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal Cancer Screening
  • Faecal Occult Blood test
  • General Practitioners Involvement
  • Patient's Participation
  • Reminder
04

Who can participate

Ages eligible
50 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. General Practitioner (GP)

    • exercising in the Val de Marne (French department of the suburb of Paris)
    • volunteered to participate at the study
  2. Patient

    • living in the Val de Marne (French department of the suburb of Paris)
    • having declared a 'preferred GP' exercising in the Val de Marne to the main statutory health insurance scheme ("régime général")
    • being eligible for colorectal cancer screening (aged 50 to 74 years, not excluded and having not proceed yet to the screening)
    • having consulted his 'preferred GP', whatever the reason, during the study period

Exclusion criteria

Exclusion Criteria:

05

Study design

Phase
Early Phase 1
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,140 participants (actual)

Study arms

  • Experimental
    Eligible patients' paper-based reminder

    Other: Eligible patients' paper-based reminder

  • No intervention
    Control group

Interventions

  • OtherEligible patients' paper-based reminder

    Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason

06

What researchers measure

Primary outcomes

  1. Patient's participation to colorectal cancer screening program

    Patient's status with colorectal cancer screening program to 15th june 2011 with two modalities 1. Update: completion of Faecal Occult Blood test or exclusion for medical reason within the duration of the study (The medical exclusions of the program are a personal or family history of Colorectal cancer, Crohn's disease, hemorrhagic rectocolitis, or hereditary nonpolyposis colorectal cancer, a colonoscopy undergone in the 5 previous years or a Fecal Occult Blood test undergone in the 2 previous years) 2. Not update

    Time frame: 1 year

07

Study locations

1 site
  • Département Universitaire d'Enseignement et de Recherche en Médecine Générale
    Créteil, 94000, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2011
First posted
Jun 2, 2011
Start
Jun 2010
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Last update
Aug 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01364454
Lead sponsor
Paris 12 Val de Marne University
Responsible party
Julien Le Breton (MD, MPH, Paris 12 Val de Marne University) — Principal investigator
First posted
Jun 2, 2011
Start date
Jun 2010
Primary completion
Jun 2011
Completion
Jun 2011
Last update
Aug 19, 2016

Study contacts

Julien Le Breton, MD, MPH
principal investigator · DUERMG

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion